AndreasGMoraitisMD

Endocrinology • Sunny Isles Beach, FL

Adrenal Disease, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology

Assistant Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Moraitis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moraitis' full profile

Already have an account?

Office
18101 Collins Ave
Sunny Isles Beach, FL 33160
Phone+1 347-754-1993

Fax+1 734-647-2145

Education & Training

National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2010 - 2012
New York Downtown HospitalResidency, Internal Medicine, 2007 - 2010
University of AthensClass of 2002

Certifications & Licensure

VA State Medical License 2011 - 2026
FL State Medical License 2015 - 2025
MI State Medical License 2012 - 2025
MD State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome Start of enrollment: 2016 Jun 01
Completed
Phase 2
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery Start of enrollment: 2016 Nov 01
Completed
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Start of enrollment: 2018 May 07
Enrolling by invitation
Phase 2
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Start of enrollment: 2018 Nov 15
Completed
Phase 3
Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Start of enrollment: 2020 Jul 27
Active, not recruiting
Phase 3
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Start of enrollment: 2020 Sep 30
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with...
Ralph A DeFronzo, Richard J Auchus, Irina Bancos, Lawrence Blonde, Robert S Busch
BMJ Open. 2024-07-16
Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Card...
Diane M Donegan, Rosario Pivonello, Antonio Stigliano, Pina Lardo, Tara Kearney
Endocrine Practice. 2024-01-01
6 citations
Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Saptarshi Mallick, Jayati Chakrabarti, Jennifer Eschbacher, Andreas G Moraitis, Andrew E Greenstein
Translational Research. 2023-06-01

Journal Articles

Clinical and hormonal responses to mifepristone therapy in two patients with ACTH independent Cushing's syndrome
Andreas G.Moraitis MD and Richard Auchus, AACE case reports, 7/19/2015

Lectures

Career Development Workshop - Careers in Industry
ENDO 2019 - New Orleans, LA - 3/24/2019
Neuroendocrinology and Pituitary
ENDO 2019 - New Orleans, LA - 3/24/2019

Press Mentions

Improvements in Excess Cortisol Activity with RelacorilantApril 29th, 2019

Professional Memberships

American Medical Association - AMA
Member
Endocrine Society - ENDO
Member
American Association of Clinical Endocrinologists - AACE
Member

Other Languages

Greek

Industry Relationships

Medical Director, Corcept Therapeutics2014 - Present